Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Banoxantrone: Phase II discontinued

Novacea said it will discontinue an open-label, U.S. Phase II trial of AQ4N to

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE